GO:0110015 positive regulation of elastin catabolic process: Elastin Degradation Control, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0110015 describes any process that activates or increases the frequency, rate or extent of elastin catabolism, the breakdown of the extracellular matrix protein elastin.
• Elastin catabolism is executed mainly by matrix metalloproteinases such as MMP-2, which are regulated by elastin-derived peptides and tissue inhibitors of metalloproteinases (TIMPs).
• Positive regulation of elastin catabolism is transcriptionally and post-transcriptionally controlled, including by NF-1 factors acting on the elastin gene and by microRNAs such as miR34a-5p.
• Dysregulated elastin degradation contributes to vascular calcification, aortic aneurysm, and ligamentum flavum hypertrophy.
• Key experimental models include MMP-2/TIMP knockout and knock-in cells, elastin promoter reporter lines, and CRISPR screens targeting protease and inhibitor networks.
• EDITGENE provides knockout, point-mutation, knock-in, overexpression cell models and CRISPR library screening to dissect positive regulation of elastin catabolic process.
Description
GO:0110015, positive regulation of elastin catabolic process, is a biological process Gene Ontology term that captures any mechanism which activates or increases the frequency, rate or extent of elastin catabolism, the chemical reactions and pathways resulting in the breakdown of elastin. Elastin is a core structural protein of the extracellular matrix, and its controlled degradation is essential for tissue remodeling, but excessive or mislocalized elastolysis underlies multiple human pathologies. Understanding the positive regulation of this process therefore requires identifying the proteases, inhibitors, and signaling inputs that tip the balance toward elastin breakdown. Researchers study GO:0110015 because elastin catabolism is not a passive event; it is actively regulated at the transcriptional, post-transcriptional, and enzymatic levels. For example, NF-1 transcription factors modulate elastin gene expression, while elastin-derived peptides can feed back to regulate MMP-2 and TIMP levels. In vascular and musculoskeletal systems, positive regulators of elastin catabolism are increasingly recognized as drivers of calcification, aneurysm, and hypertrophy. This article integrates the QuickGO definition with verified PubMed literature to outline the mechanisms, key genes, disease links, and experimental methods relevant to GO:0110015. It is designed for researchers who need a precise, citable overview of how elastin degradation is positively regulated and how to model it experimentally.
positive regulation of elastin catabolic process At A Glance
| GO ID | GO:0110015 |
|---|---|
| GO term | positive regulation of elastin catabolic process |
| Ontology | biological_process |
| Synonym | none |
| Major function | Activates or increases the frequency, rate or extent of elastin catabolism |
| Related process | Elastin catabolic process, extracellular matrix remodeling |
| Key regulators | MMP-2, TIMPs, NF-1 factors, miR34a-5p |
| Disease relevance | Vascular calcification, aortic aneurysm, ligamentum flavum hypertrophy |
What Is GO:0110015?
In our own words, GO:0110015 refers to any biological process that turns up the activity, frequency, or extent of elastin breakdown. It does not describe the degradation itself, but the regulatory inputs that enhance it, such as increased protease expression, reduced inhibitor activity, or signaling events that promote elastolysis.
Why Is positive regulation of elastin catabolic process Important in Cell Biology?
Positive regulation of elastin catabolic process is important because elastin degradation is a double-edged sword: controlled elastolysis supports tissue remodeling, but excessive or inappropriate activation drives structural failure of arteries, lungs, and connective tissues. Understanding the positive regulators of elastin catabolism helps explain how vascular calcification, aneurysm formation, and ligament hypertrophy develop, and it identifies candidate targets for therapeutic intervention.
• Elastin catabolism is required for normal extracellular matrix turnover, but its positive regulation must be tightly controlled.
• MMP-2 is a major elastin-degrading protease whose activity is modulated by elastin-derived peptides and TIMPs.
• NF-1 transcription factors regulate elastin gene transcription, indirectly influencing the substrate available for catabolism.
• miR34a-5p can potentiate pro-atherogenic manifestations by impeding CLOCK expression, linking circadian disruption to elastin-related vascular pathology.
• GDF11 regulates vascular smooth muscle cell phenotype switching and prevents aortic aneurysm formation, a process tied to elastin integrity.
• Vascular calcification is closely associated with elastin degradation and remodeling of the arterial wall.
• Ligamentum flavum hypertrophy involves increased MMP-2 and altered MMP-2/TIMP balance in response to elastin-derived peptides.
• Positive regulators of elastin catabolism are candidate biomarkers and therapeutic targets in cardiovascular and musculoskeletal disease.
• CRISPR-based models allow causal testing of protease and inhibitor genes in elastin degradation pathways.
• Understanding this GO term supports development of precision models for aneurysm, calcification, and fibrosis research.
What Happens During positive regulation of elastin catabolic process?
Initiation by Protease Upregulation
In simple terms: The process starts when cells make more elastin-degrading enzymes.
Positive regulation of elastin catabolism is initiated when cells increase the expression or activity of elastin-degrading proteases, notably matrix metalloproteinases such as MMP-2. In ligamentum flavum hypertrophy, increased MMP-2 is observed alongside altered MMP-2/TIMP regulation by elastin-derived peptides, indicating a feedback loop that can amplify elastin breakdown. This step is a key control point because it determines whether elastin catabolism proceeds at baseline or accelerated rates.
Transcriptional Control of Elastin and Proteases
In simple terms: Gene switches control how much elastin and how many degrading enzymes are made.
Transcription factors such as NF-1 factors regulate elastin gene transcription, thereby influencing the amount of elastin substrate available for catabolism. Positive transcriptional regulatory elements within exon 1 of the elastin gene further fine-tune elastin expression. When elastin synthesis is reduced or protease transcription is increased, the balance shifts toward enhanced elastin catabolism, consistent with positive regulation of the catabolic process.
Post-transcriptional and MicroRNA Regulation
In simple terms: Small RNA molecules can dial the process up or down after genes are transcribed.
MicroRNAs contribute to the post-transcriptional regulation of genes involved in elastin catabolism and vascular pathology. miR34a-5p impedes CLOCK expression in chronodisruptive mice and potentiates pro-atherogenic manifestations, linking circadian regulators to elastin-related vascular remodeling. Such microRNA-mediated control can indirectly enhance elastin catabolic activity by shifting the protease-inhibitor balance.
Protease-Inhibitor Balance and Feedback
In simple terms: The process depends on the tug-of-war between enzymes that chew elastin and inhibitors that block them.
The net positive regulation of elastin catabolism reflects the balance between active proteases such as MMP-2 and their tissue inhibitors, TIMPs. Elastin-derived peptides can regulate MMP-2 and TIMP levels, creating feedback that may sustain or dampen elastolysis. When TIMP availability falls or MMP-2 activity rises, the balance favors elastin breakdown, effectively increasing the rate of elastin catabolism.
Integration with Vascular and Matrix Remodeling Signals
In simple terms: The process is wired into broader tissue-remodeling programs.
Positive regulation of elastin catabolism is integrated with signaling pathways that control vascular smooth muscle cell phenotype and matrix remodeling. GDF11 regulates vascular smooth muscle cell phenotype switching to prevent aortic aneurysm formation, a context in which elastin integrity is critical. Vascular calcification is also closely tied to elastin degradation and arterial wall remodeling. These connections place GO:0110015 within larger programs of extracellular matrix turnover and vascular homeostasis.
Key Genes Involved in GO:0110015 positive regulation of elastin catabolic process
The following genes and proteins are experimentally implicated in the regulation of elastin catabolism and its positive control, based on the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| MMP2 | Elastin-degrading protease; increased in ligamentum flavum hypertrophy | Target for knockout and inhibitor studies in elastin catabolism |
| TIMP1 | Tissue inhibitor of metalloproteinases; modulates MMP-2 activity | Knock-in/overexpression models to test protease-inhibitor balance |
| TIMP2 | Tissue inhibitor of metalloproteinases; regulates MMP-2 | CRISPR knockout to assess elastin degradation rates |
| ELN | Elastin; substrate for catabolic process | Promoter reporter and knock-in models for expression control |
| NF1 | NF-1 transcription factor regulating elastin gene transcription | Knockout/point-mutation to study transcriptional control |
| CLOCK | Circadian regulator impeded by miR34a-5p; linked to pro-atherogenic manifestations | Knockout models to test circadian effects on elastin catabolism |
| GDF11 | Regulates vascular smooth muscle cell phenotype switching; prevents aortic aneurysm | Overexpression and knockout models in vascular remodeling |
| MMP9 | Matrix metalloproteinase implicated in elastin degradation | Knockout and pharmacological inhibition studies |
| MMP12 | Elastin-degrading metalloproteinase | CRISPR models for elastolysis research |
| CTSK | Cathepsin K, elastin-degrading protease | Knockout and point-mutation models |
| CTSS | Cathepsin S, elastin-degrading protease | Overexpression and knockout studies |
| NE | Neutrophil elastase, elastin-degrading serine protease | Knockout and inhibitor models |
| TGFB1 | Signaling factor in matrix remodeling and vascular calcification | Knock-in and overexpression models |
| BMP2 | Promotes vascular calcification associated with elastin degradation | Knockout and overexpression models |
| RUNX2 | Osteogenic transcription factor in vascular calcification | Point-mutation and knockout models |
| SPP1 | Osteopontin, matrix protein in calcification and remodeling | Overexpression and knockout models |
| MGP | Matrix Gla protein, inhibitor of calcification | Knockout models for calcification and elastin degradation |
| FBN1 | Fibrillin-1, microfibril component interacting with elastin | Knock-in and point-mutation models |
How Is positive regulation of elastin catabolic process Regulated?
Positive regulation of elastin catabolic process is controlled at multiple levels. Transcriptionally, NF-1 factors and positive regulatory elements within the elastin gene influence elastin availability. Post-transcriptionally, microRNAs such as miR34a-5p can modulate genes linked to vascular pathology and elastin remodeling. Enzymatically, the balance between MMP-2 and TIMPs determines net elastolytic activity, with elastin-derived peptides providing feedback regulation. Systemically, signaling pathways involving GDF11 and vascular smooth muscle cell phenotype switching integrate elastin catabolism with vascular homeostasis. Vascular calcification pathways further intersect with elastin degradation, highlighting the broad regulatory network around this process.
positive regulation of elastin catabolic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| MMP2 | Ligamentum flavum hypertrophy; elastin degradation | MMP2 knockout and TIMP overexpression cell models |
| GDF11 | Aortic aneurysm; vascular smooth muscle phenotype | GDF11 knockout and overexpression mouse models |
| CLOCK | Atherogenesis; circadian disruption | CLOCK knockout and miR34a-5p mimic models |
| ELN | Vascular calcification; elastin remodeling | ELN promoter reporter and knock-in models |
| MGP | Vascular calcification; elastin degradation | MGP knockout models for calcification studies |
Vascular Calcification and Arterial Remodeling
Vascular calcification is closely associated with elastin degradation and remodeling of the arterial wall. Positive regulation of elastin catabolism can release elastin-derived peptides that influence calcification and matrix remodeling, contributing to arterial stiffness and cardiovascular risk. Understanding these mechanisms may inform therapies targeting elastin degradation in calcific vascular disease.
Aortic Aneurysm and Smooth Muscle Phenotype
GDF11 regulates vascular smooth muscle cell phenotype switching to prevent aortic aneurysm formation, a disease in which elastin integrity is critical. Excessive elastin catabolism weakens the aortic wall and promotes aneurysm progression, making positive regulators of elastin catabolism candidate therapeutic targets. Experimental models of GDF11 manipulation provide insight into how elastin degradation is controlled in the vessel wall.
Ligamentum Flavum Hypertrophy and Musculoskeletal Disease
Increased MMP-2 in ligamentum flavum hypertrophy and the regulation of MMP-2/TIMPs by elastin-derived peptides demonstrate a direct link between elastin catabolism and musculoskeletal pathology. Positive regulation of elastin catabolism in this context may contribute to tissue hypertrophy and spinal stenosis. Targeting MMP-2 or TIMP balance is a potential experimental strategy in these models.
Atherogenesis and Circadian Disruption
miR34a-5p impedes CLOCK expression in chronodisruptive mice and potentiates pro-atherogenic manifestations, linking circadian disruption to vascular pathology that involves elastin remodeling. This suggests that positive regulation of elastin catabolism may be modulated by circadian and microRNA networks in atherogenesis. Experimental models of chronodisruption can be used to test this relationship.
From positive regulation of elastin catabolic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does MMP2 loss reduce elastin catabolism? | MMP2 knockout cell line |
| Does TIMP overexpression block elastolysis? | TIMP1/TIMP2 overexpression cell model |
| How do elastin promoter variants affect catabolism? | ELN promoter knock-in reporter |
| Does GDF11 signaling alter elastin degradation? | GDF11 knockout or overexpression vascular cells |
| Does miR34a-5p modulate CLOCK and elastin remodeling? | miR34a-5p mimic/inhibitor with CLOCK knockout |
| Which proteases drive calcification-associated elastolysis? | CRISPR library screen in vascular calcification model |
How to Study the positive regulation of elastin catabolic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Promoter reporter assay | Transcriptional activity of elastin regulatory elements | Testing NF-1 and exon 1 element effects |
| Gelatin zymography | MMP-2 and MMP-9 activity | Assessing elastin-degrading protease activity |
| ELISA | TIMP and elastin-derived peptide levels | Quantifying protease-inhibitor balance |
| CRISPR knockout screen | Genes affecting elastin catabolism | Discovery of positive regulators |
| RNA-seq | Transcriptional changes in protease and matrix genes | Pathway analysis in disease models |
| Western blot | Protein levels of MMPs, TIMPs, GDF11 | Validation of regulatory changes |
| Immunohistochemistry | Elastin fiber integrity in tissue | Assessing elastin loss in disease models |
| qPCR | mRNA levels of ELN, MMP2, TIMP1 | Rapid screening of regulatory effects |
Transcriptional and Promoter Reporter Assays
Luciferase reporter assays using elastin promoter and exon 1 regulatory elements can quantify transcriptional control of elastin availability, a key input to positive regulation of elastin catabolism. These assays are typically performed in vascular or fibroblast cell lines with NF-1 factor manipulation.
Protease Activity and Zymography
Gelatin zymography and protease activity assays measure MMP-2 and related elastin-degrading enzyme activity in conditioned media or tissue lysates. These methods are used to assess how elastin-derived peptides and TIMPs regulate net elastolytic capacity.
CRISPR Screens for Regulatory Networks
CRISPR knockout library screens can identify genes that positively regulate elastin catabolism, including proteases, inhibitors, and signaling factors. Hits are validated with individual knockout or overexpression models to confirm causality.
In Vivo and Ex Vivo Remodeling Models
Aortic aneurysm and vascular calcification models, including GDF11 manipulation and chronodisruption paradigms, allow assessment of elastin degradation in a physiological context. These models link molecular regulators to tissue-level elastin loss and disease phenotypes.
How CRISPR Can Be Used to Study GO:0110015 positive regulation of elastin catabolic process
Knockout
CRISPR knockout of MMP2, TIMP1, or TIMP2 can directly test their causal roles in positive regulation of elastin catabolism. Knockout cell models are used to measure changes in elastin degradation and feedback regulation by elastin-derived peptides.
Point Mutation
Point mutations in elastin regulatory elements or protease active sites can dissect specific residues required for transcriptional control or catalytic activity. These models help distinguish regulatory from structural functions in elastin catabolism.
Knock-in
Knock-in of reporter genes or tagged proteases allows real-time monitoring of elastin catabolic activity and protein localization. Knock-in models of elastin promoter variants can reveal how sequence changes affect catabolic regulation.
Overexpression
Overexpression of MMP2, GDF11, or miR34a-5p can amplify or perturb elastin catabolic pathways, enabling gain-of-function studies. These models are useful for testing whether a candidate regulator is sufficient to increase elastin breakdown.
How EDITGENE Supports positive regulation of elastin catabolic process Research
Researchers studying positive regulation of elastin catabolic process-related genes often need to determine whether a candidate gene is causally involved in elastin degradation or merely correlated with it. CRISPR-based models provide the necessary gain- and loss-of-function evidence to move from association to mechanism.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of elastin catabolic process research.
Frequently Asked Questions About positive regulation of elastin catabolic process
What is GO:0110015 positive regulation of elastin catabolic process?
It is a Gene Ontology biological process term describing any process that activates or increases the frequency, rate or extent of elastin catabolism, the breakdown of elastin.
What genes are involved in positive regulation of elastin catabolic process?
Key genes include MMP2, TIMP1, TIMP2, ELN, NF1, CLOCK, and GDF11, based on studies of elastin degradation and vascular remodeling.
How is elastin catabolism regulated?
It is regulated transcriptionally by NF-1 factors and elastin promoter elements, post-transcriptionally by microRNAs such as miR34a-5p, and enzymatically by the MMP-2/TIMP balance.
What diseases are linked to elastin degradation?
Vascular calcification, aortic aneurysm, ligamentum flavum hypertrophy, and atherogenesis are linked to elastin catabolism and its positive regulation.
Which proteases degrade elastin?
Matrix metalloproteinases such as MMP-2, along with other proteases including cathepsins and neutrophil elastase, contribute to elastin degradation.
How can I study positive regulation of elastin catabolic process in the lab?
Common methods include promoter reporter assays, zymography, ELISA for TIMPs, CRISPR knockout screens, RNA-seq, and immunohistochemistry for elastin integrity.
What is the role of MMP-2 in elastin catabolism?
MMP-2 is a major elastin-degrading protease whose activity is regulated by elastin-derived peptides and TIMPs, and it is increased in ligamentum flavum hypertrophy.
Does GDF11 affect elastin degradation?
GDF11 regulates vascular smooth muscle cell phenotype switching to prevent aortic aneurysm formation, a context where elastin integrity is critical.
Can microRNAs regulate elastin catabolism?
Yes, miR34a-5p impedes CLOCK expression and potentiates pro-atherogenic manifestations, linking microRNA networks to elastin-related vascular pathology.
What CRISPR models are available for elastin catabolism research?
Knockout, point-mutation, knock-in, and overexpression models for MMP2, TIMPs, ELN, GDF11, and CLOCK can be generated to test causal roles in elastin degradation.
Conclusion
GO:0110015 positive regulation of elastin catabolic process is a biologically and clinically important ontology term that captures the active control of elastin breakdown. The verified literature highlights MMP-2, TIMPs, NF-1 factors, GDF11, and miR34a-5p as key players in this regulation, with strong links to vascular calcification, aortic aneurysm, ligamentum flavum hypertrophy, and atherogenesis. By combining precise CRISPR models with transcriptional, proteolytic, and imaging assays, researchers can move from correlation to causation in elastin catabolism research. EDITGENE supports this effort with knockout, point-mutation, knock-in, overexpression, and library screening services tailored to elastin degradation pathways.
References
- 1. Quaglino D et al.. 2020. The biology of vascular calcification.. Int Rev Cell Mol Biol 354:261-353 PMID: 32475476
- 3. Degterev A et al.. 1999. The role of NF-1 factors in regulation of elastin gene transcription.. Matrix Biol 18(3):295-307 PMID: 10429948
- 4. Zhuo WH et al.. 2024. Increased matrix metalloproteinase-2 in ligamentum flavum hypertrophy and the regulation of MMP-2/TIMPs by elastin-derived peptides.. J Orthop Res 42(9):2061-2071 PMID: 38546147
- 5. Pierce RA et al.. 2006. Positive transcriptional regulatory element located within exon 1 of elastin gene.. Am J Physiol Lung Cell Mol Physiol 291(3):L391-9 PMID: 16899711
- 7. Su X et al.. 2026. GDF11 Regulates Vascular Smooth Muscle Cell Phenotype Switching to Prevent Aortic Aneurysm Formation.. Cardiovasc Drugs Ther 40(3):883-895 PMID: 41240221
- 8. Vyas H et al.. 2023. miR34a-5p impedes CLOCK expression in chronodisruptive C57BL/6J mice and potentiates pro-atherogenic manifestations.. PLoS One 18(8):e0283591 PMID: 37561715
